Based on these findings, Naschberger and colleagues could attribute GBP-1, resulting from IFN-γ upregulation in colorectal carcinoma (CRC), to an IFN-γ-dominated Th1-like immune reaction possessing potential angiostatic/antiangiogenic activity. The gene discussed is IFNG; the disease is colorectal carcinoma.